Rocket Fuel
Advanced Search
Print    Email
Decrease (-) Restore Default Increase (+)
Find a Physician

Breast Cancer Clinical Trials

 Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies. 

Trial  #

Trial Sub- type 

Title

MLN0128
Sponsor:
Millennium Pharmaceuticals, Inc.
New.jpg

Postmenopausal Women With
ER+/HER2- Advanced or Metastatic Breast Cancer

A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant; Sponsor Millennium Pharmaceuticals, Inc.

ECOG E1Z11

NCI Closed enrollment to Caucasians

  • Estrogen and/or progesterone receptor positive, histologically confirmed stage I-III breast adenocarcinoma
  • Completed recommended local and adjuvant therapy for breast cancer
  • Plan to treat with anastrozole for at least 12 months

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

ML28257
Sponsor:
Genentech
Sub -Investigator

Metastatic
HER2-positive

An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (HER2+) Metastatic Breast Cancer

CBKM120F2303
Sponsor:
Novartis Pharmaceuticals
Sub -Investigator

 

Metastatic
HER2-negative

HR - positive

A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment

CRAD001Y2413
Sponsor:
Novartis
Sub -Investigator

Metastatic
HER2- negative
HR – positive
Front - line

An open-label, phase II, single-arm study of everolimus in  combination with letrozole in the treatment of postmenopausal  women with estrogen receptor positive metastatic breast cancer

S1207
Lead Group:
SWOG

HER2- negative
ER or PR– positive
Adjuvant Therapy

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone  Receptor-Positive and HER2/neu Negative Breast Cancer

RTOG 1005
NCI

pStage I, II breast cancer
- pStage 0 breast cancer with nuclear grade 3 DCIS and patient age < 50 years
- ypStage 0, I, II breast cancer resected by lumpectomy after neoadjuvant systemic therapy

A phase III trial of accelertated whole breast irradiation with hypofraction pluc concurrent boost versus standard whole breast irradiation pluc sequential boost for early-state breast cancer.

 

 

CDX011-04

Metastatic Triple-Negative Breast Cancer

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The "METRIC" Study)

?
?
  Holy Cross Hospital
  Holy Cross Germantown Hospital
  Icon-LinkedIn.png 
© 2014  Holy Cross Health | 1500 Forest Glen Road, Silver Spring, MD 20910 | 301-754-7000
trinity-health.org